scholarly journals Palliative Radiation Therapy in Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Survival, Epidemiology and End Results (SEER) Analysis

2017 ◽  
Vol 99 (2) ◽  
pp. E495
Author(s):  
S. Shamp ◽  
R.B. Patel ◽  
T. Biswas
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Palliative Radiation ◽  
Palliative Radiation Therapy ◽  
Extensive Stage ◽  
End Results

scholarly journals Aggressive Palliation in Extensive Stage Small Cell Lung Cancer, Practice Guidelines versus Clinical Practice: A Case Report and Review of the Literature

2011 ◽  
Vol 2011 ◽  
pp. 1-4
Author(s):  
Edward F. Miles ◽  
Laura L. Jacimore ◽  
John W. Nelson
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Metastatic Disease ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Response To Chemotherapy ◽  
Thoracic Radiation ◽  
Extensive Stage

Small cell lung cancer (SCLC) constitutes approximately 16% of all primary lung cancers, with more than 35,000 new cases per year. Two-thirds of patients present with extensive stage disease (ES-SCLC) due to a tendency to metastasize early. Outcomes remain poor, with a median survival of approximately 10 months and a two-year overall survival of <10%. Current recommendations call for combination chemotherapy alone in patients without localized symptoms. Thoracic radiation therapy following a good clinical response is controversial. We report on a patient with ES-SCLC that had an excellent response to chemotherapy and underwent whole brain radiotherapy for a known brain metastasis and consolidative radiotherapy to the thorax. His latest follow-up demonstrates only a stable residual pulmonary nodule and no evidence of active metastatic disease. ES-SCLC is a relatively common presentation with a variable burden of metastatic disease. In the absence of randomized trials demonstrating the efficacy of thoracic radiation therapy, the community radiation oncologist is placed in a difficult position when addressing these patients, particularly those with otherwise good performance status and a good response to initial systemic chemotherapy. More research in this area is sorely needed to help guide treatment recommendations.

Sign in / Sign up

Export Citation Format

Share Document